New Times,
New Thinking.

5 September 2014

#notallslaveowners: the Economist complains that a book on slavery makes white people look bad

A book review in the Economist has called a book on slavery biased for painting white people as the villains.

By Media Mole

The Economist has run an extroardinary piece that apparently defends slave owners. Its review of a book on slavery, The Half Has Never Been Told: Slavery and the Making of American Capitalism by Edward Baptist, suggests the book is biased for making white people look bad.

Here’s the review’s conclusion:

. . . Mr Baptist has not written an objective history of slavery. Almost all the blacks in his book are victims, almost all the whites villains. This is not history; it is advocacy.

This mole always thought the worst thing about the slave trade was how it put white people in a bad light…


UPDATE: 14.26, 5 September 2014

Select and enter your email address Your weekly guide to the best writing on ideas, politics, books and culture every Saturday. The best way to sign up for The Saturday Read is via saturdayread.substack.com The New Statesman's quick and essential guide to the news and politics of the day. The best way to sign up for Morning Call is via morningcall.substack.com
Visit our privacy Policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications.
THANK YOU

The Economist has now withdrawn the book review. An editor’s note explains the decision:

There has been widespread criticism of this [review], and rightly so. Slavery was an evil system, in which the great majority of victims were blacks, and the great majority of whites involved in slavery were willing participants and beneficiaries of that evil. We regret having published this and apologise for having done so. We have therefore withdrawn the review. . . 

Content from our partners
Nutrition must be central to Labour's health mission
How we can continue to innovate in the care of rare diseases
The right deal for all